Insider Trading Activity in: Fluidigm Corporation $FLDM

5ee8286784b2b12652e8ad6e00a0a66d

Fluidigm Corporation (FLDM) insider have most recently took part in a trading activity. On Nov 30, 2017 Levin Capital Strategies, L.p., bought 76,629 shares having total worth of $455,943 at the price of $5.95 per share, following the transaction a total of 11,642,463 shares owned by Levin Capital Strategies, L.p.. Before this latest buy, Levin Capital Strategies, L.p. purchased FLDM at 14 other times during the past twelve months, for a total investment of $156.41M at an average of $4.75 per share.

The stock has experienced a total of 11 insider trades in the past three months. These trades include 11 buy trades. Furthermore, over the past 12 months , the stock was traded 24 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 23 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 11 0 59.95%
12 Month 23 1 -38.34%

Shares of Fluidigm Corporation (FLDM) traded up 6.44% on Nov 30, 2017, hitting $5.95. 327,899 shares of the company’s stock traded hands. Fluidigm Corporation has a 52 week low of $2.71 and a 52 week high of $10.72. The company’s market cap is $248 million.

Fluidigm Corporation (FLDM) last announced its earnings results on Nov 2, 2017. The company reported -0.25 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.53 by $0.28. The company had revenue of $25 million for the quarter, compared to the consensus estimate of $26 million. During the same quarter in the previous year, the company posted -0.38 earnings per share. The company’s revenue for the quarter was up 12% on a year-over-year basis.

2017-11-02 2017-08-03 2017-05-04 2017-02-08 2016-11-03 2016-08-04 2016-05-05 2016-02-04 2015-10-29 2015-08-06
earnings per share -0.25 -0.31 -0.33 -0.32 -0.38 -0.34 -0.40 -0.24 -0.15 -0.20
Revenue(M) 24.75 23.91 25.53 25.08 22.19 28.17 29 30.72 28.64 28.62

Fluidigm Corporation is a Delaware Corporation formed in 1999. The Company is a microfluidic systems for growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing, in the life science and agricultural biotechnology, or Ag-Bio, industries. Its proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or IFCs, assays, and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. The current markets for its products include life science research, clinical research, and Ag-Bio. The Company’s primary area of focus within life science research is genetic analysis, the study of genes and their functions. Genetic analysis techniques, such as SNP genotyping, genotyping by sequencing, and genotyping by real-time PCR analysis, have become increasingly useful in Ag-Bio applications, including wildlife population studies, agricultural quality control, and commercial genetic engineering and identification. It actively market four microfluidic systems, including thirteen different commercial IFCs for nucleic acid analysis, as well as three families of assay chemistries. Its systems are based on one or more IFCs designed for particular applications and include specialized reagents, instrumentation, and software. The Company distributes its microfluidic systems through its direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. It has have sold its C1 Single-Cell Auto Prep, BioMark, BioMark HD, EP1, and Access Array systems to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. The Company has sold approximately 685 systems to customers in over 30 countries. Its microfluidic systems and instrumentation for commercial sale, as well as for internal research and development purposes, are manufactured at its facilities in Singapore. The Company also manufacture IFCs for research and development and its assay chemistries at its headquarters in South San Francisco, California. It competes with both established and development stage life science companies that design, manufacture, and market instruments for gene expression analysis, genotyping, other nucleic acid detection, and additional applications.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.